jak2, calr, and mpl mutation profiles in bcr-abl negative myeloproliferative neoplasms, a referral center experience in the middle east

Background & objective: jak2, calr, and mpl genes play pivotal roles in the pathogenesis of bcr-abl negative myeloproliferative neoplasms. this study was conducted to evaluate the frequency of jak2, calr, and mpl mutations in bcr-abl negative myeloproliferative neoplasms and their association with demographic data and hematologic parameters in a referral center, in the middle east. methods: seventy-one patients with bcr-abl negative myeloproliferative neoplasms were evaluated for jak2 v617f, calr type 1, calr type 2, and mpl by allele-specific pcr and conventional pcr from 2018 to 2019.results: twenty-three patients were categorized as polycythemia vera, jak2 v617f was observed in 91.3% of these cases. thirty-eight patients were classified as essential thrombocythemia of which 52.6% showed jak2 v617f, 18.4% demonstrated calr type 1, 7.9% denoted calr type 2 and there was no mutation reported in 21.1%. seven patients were recognized as primary myelofibrosis and exhibited jak2 v617f mutation in 57.1%, calr type 1 in 14.3 %, calr type 2 in 14.3% and no mutation in 14.3%. three patients were diagnosed as mpn, unclassifiable and 33.3% revealed jak2 v617f mutation, and no mutation was found in 66.6%. the age (59.15±13.10) and neutrophil percent (70.78±10.14) were higher in patients with jak2 v617 mutation compared to other mutations (p=0.000, and p=0.03). platelet count was significantly higher in patients with calr type 1 mutation (1240400± 402053) (p=0.000). conclusion: jak2 v617f was associated with patients’ higher age and higher neutrophil count in cbc. calr mutation had an association with higher platelet count. no mpl mutation was found in this study and it seems that its frequency is lower than what is expected in this region.